Ratings ABIONYX Pharma Börse Stuttgart

Equities

609 FR0012616852

Market Closed - Börse Stuttgart Other stock markets 10:01:47 2024-06-07 EDT			5-day change	1st Jan Change
1.146 ^EUR	-1.72%		-1.72%	-36.40%

03-14	Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	CF
03-11	Abionyx: reduced net loss in 2023	CF

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ABIONYX PHARMA	-36.40%	42.26M	-
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B	B+
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B	B+
BIONTECH SE	-4.93%	24.21B	B+
ARGENX SE	+3.23%	22.78B	B
GENMAB A/S	-10.44%	17.96B	A-
WUXI APPTEC CO., LTD.	-41.74%	16.43B	A-
BEIGENE, LTD.	-13.31%	16.37B	B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B	C+
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes